The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease

Launched by HANGZHOU JIAYIN BIOTECH LTD · Feb 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called EXG110 for patients with Fabry disease, a condition that affects various organs in the body. The goal of this study is to see how safe and effective EXG110 is when given through an intravenous (IV) line. This trial will involve multiple centers, and it is in the early phases, meaning they are just starting to gather information about the treatment.

To participate in this trial, individuals must be at least 18 years old and have been diagnosed with Fabry disease, showing at least one related symptom. They can be new to treatment or have received other therapies before. Participants should also have issues related to their kidneys or heart. The trial is not yet actively recruiting participants, but it is important to know that certain health conditions, like liver disease or serious infections, may exclude someone from joining. If eligible, participants can expect to receive the study treatment and contribute to important research that could help improve care for others with Fabry disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years old, male or female
• • 2. Clinical symptoms (at least one Fabry disease related symptom) and genetic diagnosis of Fabry disease
• • 3. Prior or no prior ERT treatment
• • 4. Have renal or cardiac involvement
• • 5. The participant voluntarily participate and are fully informed, fully understood the study, can comply with the requirements of the protocol, and voluntarily provide biological samples for testing according to the requirements of the protocol
• Exclusion Criteria:
• • 1. Screening period laboratory test results: a) aspartate aminotransferase or alanine aminotransferase \> 1.5× upper limit of normal (ULN);b) Total bilirubin \> 1.5× upper limit of normal (ULN);c) Alkaline phosphatase \> 2× upper limit of normal (ULN);d) Hypoalbuminemia ≥ grade 2
• • 2. Serum virology test: a) Hepatitis B: Hepatitis B virus surface antigen (HBsAg) positive, and hepatitis B virus-deoxyribonucleic acid (HBV-DNA) higher than the upper limit of normal detection;b) Hepatitis C: if the hepatitis C virus (HCV) antibody is positive, and the hepatitis C virus-ribonucleic acid (HCV-RNA) is higher than the upper limit of normal test value;c) Syphilis: positive for syphilis screening (Tp-Ab) and positive for syphile-specific antibodies;d) HIV: Known human immunodeficiency virus (HIV) positive history or HIV screening positive
• • 3. Current or have a history of serious cardiovascular disease and surgical history
• • 4. Current underlying liver disease or history of liver disease, as assessed by the investigator, that may affect the safety assessment of the product
• • 5. Acute/chronic infection or other chronic disease that the investigator evaluated will increase the risk of participants in the study
• • 6. Those who have a history of epilepsy, mental illness (such as schizophrenia, depression, mania or anxiety, etc.) or obvious mental disorders, and are incapacitated or cognitively incapacitated due to other reasons.
• • 7. Participant with a history of malignant tumor or currently suffering from any malignant tumor (except for the following tumor diseases: skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ , skin squamous cell carcinoma has been controlled after treatment);
• • 8. Participant with active autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, immune vasculitis, inflammatory bowel disease, etc.);
• • 9. known history of allergy to the components of the investigational products
• • 10. Participant with a history of drug use or drug abuse or alcoholism
• • 11. Has received, or currently receiving, a clinical trial of another investigational drug/medical device or treatment (other than vitamins and minerals) within 3 months prior to signing the informed consent form (or within 5 half-lives of the investigational drug, whichever is longer)
• • 12. Previous treatment with gene therapy products
• • 13. Those who had received live attenuated vaccine/vaccine within 12 weeks prior to screening or planned to receive it during the study
• • 14. Other clinical conditions that the investigators evaluated needed to be excluded